IWA
ANTX icon

Inspirion Wealth Advisors’s AN2 Therapeutics ANTX Stock Holding History

Inspirion Wealth Advisors’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,950
Closed -$25.8K – 160
2025
Q1 		$25.8K Buy
+18,950
New +$23.9K ﹤0.01% 157

Other funds holding ANTX

AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LCM
Landscape Capital Management Englewood, New Jersey $1.58B AUM 26.88% 1-Year Est. Return
Bank of Nova Scotia
Bank of Nova Scotia Toronto, Ontario, Canada $57.2B AUM 35.3% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Inspirion Wealth Advisors's ANTX Position: Q2 2025 in Review

Inspirion Wealth Advisors sold out of AN2 Therapeutics (ANTX) in Q2 2025, closing a stake of 18,950 shares — an estimated $25.8K sold.

Inspirion Wealth Advisors first reported a position in ANTX in Q1 2025 and held it in 1 quarter. The position peaked at $25.8K in Q1 2025. 36 funds tracked by Wall St. Rank hold ANTX as of Q2 2025.

  • Inspirion Wealth Advisors reported no remaining AN2 Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Inspirion Wealth Advisors sold 18,950 AN2 Therapeutics shares in Q2 2025, an estimated $25.8K.
  • Inspirion Wealth Advisors first reported a position in AN2 Therapeutics in Q1 2025 and held it in 1 quarter.
  • Inspirion Wealth Advisors's AN2 Therapeutics position peaked at $25.8K in Q1 2025.
  • 36 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2025.

Based on Inspirion Wealth Advisors's 13F filing for Q2 2025, filed 9 Jul 2025.